Study Identifies Barriers to Endocrine Therapy Adherence in Breast Cancer Survivors
In this study, researchers found that 59% of the participants reported at least 1 barrier to endocrine therapy adherence, though over half reported that taking endocrine therapy was a joint decision between themselves and their doctor. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA ODAC Votes on Safety and Efficacy of Ramucirumab Plus Erlotinib for EGFR+ NSCLC
The FDA Oncologic Drugs Advisory Committee voted 6 to 5 that ramucirumab plus erlotinib demonstrated a favorable benefit and risk profile for patients with untreated metastatic EGFR-positive non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Findings Establish PT2385 as a Highly Specific HIF-2 Inhibitor for Patients with Clear Cell RCC
The findings reported in this study demonstrated a core dependency on HIF-2 in metastatic clear cell renal cell carcinoma and established PT2385 as a highly specific HIF-2 inhibitor. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Rituximab with BEAM Conditioning Prior to Auto-HCT for DLBCL not Recommended
This recommendation was based on an analysis of patients with diffuse large B-cell lymphoma undergoing auto-HCT in which the addition of rituximab to the BEAM conditioning regimen had no impact on transplantation outcomes. (Source: CancerNetwork)
Source: CancerNetwork - February 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Gaps in the Delivery of Palliative Cancer Care and Opportunities for Improvement
A survey study documented slow progress in the advancement of palliative care programs and emphasized that access to timely palliative care continues to be a challenge for patients with cancer, especially those at non-National Cancer Institute cancer centers. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

High Intake of Dairy Milk Associated with Greater Risk of Breast Cancer
In this study, higher intakes of dairy milk were correlated with greater risk of breast cancer, when adjusted for soy intake. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

TERT Promoter Mutations Detectable 10 Years Prior to Bladder Cancer Diagnosis
This study provides the first evidence of the urinary TERT promoter mutations to be used as simple and cost-effective non-invasive biomarkers for the early detection of bladder cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves sNDA for Neratinib in Combination with Capecitabine for HER2+ Breast Cancer
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting. (Source: CancerNetwork)
Source: CancerNetwork - February 26, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Profiling of Osteosarcoma Demonstrates Why Immunotherapy is Ineffective
Researchers found that poor infiltration of the tumor by immune cells, low activity from available T-cells, a lack of immune-stimulating neoantigens, and multiple immune-suppressing pathways all combine to dampen responses to immunotherapy in this disease landscape. (Source: CancerNetwork)
Source: CancerNetwork - February 25, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Increased Radiation Dose Associated with Increased Fatigue and Dyspnea
In this study, increased radiation dose was correlated with an increase in fatigue and dyspnea, as well as a decrease in physical activity, particularly in lung cancer or lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - February 25, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Accepts BLA for Fixed-Dose Subcutaneous Combination in HER2-Positive Breast Cancer
The FDA accepted a biologics license application for the fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase, administered by subcutaneous injection in combination with IV chemotherapy, for the treatment of eligible patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 25, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

LUNGevity ’s Scorecard Shows Improvements Needed to Address Lung Cancer in United States
LUNGevity Foundation released a Lung Cancer Scorecard to examine how effectively (or ineffectively) states are addressing lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 25, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Karen Kelly, MD, Discusses When to Start Immunotherapy
Karen Kelly, MD, sat down to discuss her presentation on when to start immunotherapy in a real world, patient setting. (Source: CancerNetwork)
Source: CancerNetwork - February 24, 2020 Category: Cancer & Oncology Authors: Karen Kelly, MD Source Type: news

Long-term Follow-up from Phase II JULIET Study Suggests Durable Improvement in HRQoL
These data, in combination with durable complete responses and overall survival data, suggested that tisagenlecleucel improved health-related quality of life in adult patients with relapsed or refractory diffuse large B-cell lymphoma who respond to treatment. (Source: CancerNetwork)
Source: CancerNetwork - February 24, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Brigatinib to Treat Non-Small Cell Lung Cancer
The FDA recently granted priority review to Takeda ’s supplemental new drug application for brigatinib to treat ALK-positive metastatic non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 24, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

FDA Accepts sNDA for Niraparib to Treat Women with Ovarian Cancer
The FDA accepted a supplemental new drug application for niraparib, treating women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status, based on data from the PRIMA study. (Source: CancerNetwork)
Source: CancerNetwork - February 24, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Study Identifies Differences in the Prevalence of Skin Cancer Across Sexual Orientations, Gender
In this study, the skin cancer rates were higher among gay and bisexual men, compared with heterosexual men, but lower among bisexual women than heterosexual women. (Source: CancerNetwork)
Source: CancerNetwork - February 23, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Walter Curran, MD, on Integration of Immunotherapy with Radiation Therapy
Walter Curran, MD, detailed his presentation on immunotherapy and radiation therapy, and how integrating the 2 treatment options presents an exciting opportunity moving forward. (Source: CancerNetwork)
Source: CancerNetwork - February 22, 2020 Category: Cancer & Oncology Authors: Walter Curran, MD Source Type: news

National Cancer Prevention Month: What You Need to Know
With February being National Cancer Prevention Month, here are the latest updates in cancer prevention. (Source: CancerNetwork)
Source: CancerNetwork - February 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Interleukin-6 May Reliably Identify Patients with High-Grade Serous Ovarian Cancer
A new tool, in combination with those already existing, could distinguish between patients with malignant and benign ovarian masses, as well as those with a benign ovarian mass and normal ovaries. (Source: CancerNetwork)
Source: CancerNetwork - February 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Active Role in Decision Making for Prostate Cancer Surgery Leads to Less Decision Regret
In this study, researchers suggested that patients who play a more active role in making decisions about their prostate cancer surgery are less likely to experience “decision regret” about their choices. (Source: CancerNetwork)
Source: CancerNetwork - February 21, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Gilberto Lopes, MD, MBA, FAMS, on Stopping Immunotherapy in Patients With Lung Cancer
Gilberto Lopes, MD, MBA, FAMS, discussed his presentation about when to stop immunotherapy treatments for patients with lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 21, 2020 Category: Cancer & Oncology Authors: Gilberto Lopes, MD, MBA, FAMS Source Type: news

Nurses May Under-Rate Nutritional Status in Pediatric Patients
Nurses were found to be significantly more likely to under-rate the nutritional status of their pediatric patients, suggesting the need for guidelines for nutritional assessment of children. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Minority Women with Breast Cancer Show More Variants of Uncertain Significance
Given the uncertainty about the clinical implications of pathogenic or likely pathogenic variants in moderate penetrance genes and variants of uncertain significance, the findings may underscore the need for targeted genetic counseling education, specifically among young minority women. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Therapy-Associated Polyposis May Mimic Hereditary CRC Symptoms in AYA Cancer Survivors
Therapy-associated polyposis was found to have similar features to various hereditary colorectal cancer symptoms, and recognition of it could have implications for cancer risk and screening among childhood and young adult cancer survivors. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Rogerio Lilenbaum, MD, Discusses Immunotherapy and Targeted Therapy for Lung Cancer
Rogerio Lilenbaum, MD, talked about the state of lung cancer in regards to immunotherapy and targeted therapy at the 17th Annual Winter Lung Conference in Miami Beach, Florida. (Source: CancerNetwork)
Source: CancerNetwork - February 20, 2020 Category: Cancer & Oncology Authors: Rogerio Lilenbaum, MD Source Type: news

FDA Grants Priority Review to Selinexor Oral Tablets for DLBCL
The FDA granted a priority review to selinexor oral tablets for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified, who have received at least 2 prior therapies. (Source: CancerNetwork)
Source: CancerNetwork - February 19, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Patrick I. Borgen, MD, on What We Can Look Forward to in Breast Cancer Treatment
The breast cancer expert, in an interview with CancerNetwork ®, discussed advances in the field of breast cancer and what we can expect to see in the pipeline moving forward. (Source: CancerNetwork)
Source: CancerNetwork - February 19, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Atezolizumab to Treat Advanced Non-Small Cell Lung Cancer
Roche recently announced the FDA accepted their supplemental biologics license application and granted priority review to atezolizumab for the treatment of non-small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 19, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

FDA Grants Breakthrough Therapy Designation to Enfortumab Vedotin
The FDA granted breakthrough therapy designation to enfortumab vedotin based on results from the dose-escalation cohort and expansion cohort A of the phase Ib/II EV-103 trial. (Source: CancerNetwork)
Source: CancerNetwork - February 19, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Lurbinectedin to Treat Small Cell Lung Cancer
The FDA granted a priority review to the new drug application for lurbinectedin as a treatment for patients with small cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

Pembrolizumab Doubles Pathologic Complete Response Rates When Added to Standard NACT
According to the researchers, these data suggest that checkpoint blockade in women with early-stage, high-risk, ERBB2-negative breast cancer is very likely to succeed in a phase III trial. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Peter Voorhees, MD, Discusses Results from the Ongoing GRIFFIN Study
The study is evaluating daratumumab plus lenalidomide, bortezomib, and dexamethasone in autologous stem cell transplant eligible patients newly diagnosed with multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Peter Voorhees, MD Source Type: news

FDA Grants 2 Fast Track Designations for ALX148
The FDA granted 2 Fast Track designations for ALX148 for the first-line treatment of patients with head and neck squamous cell carcinoma, and for the second-line treatment of patients with HER2-positive gastric or gastroesophageal junction carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 18, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Andrew J. Cowan, MD, Discusses the Phase I Clinical Trial of GSI and BCMA CAR T-Cells
The expert explained the rationale for the phase I first-in-human clinical trial evaluating the combination of a gamma-secretase inhibitor and B-cell maturation antigen CAR T-cells in patients with heavily pretreated multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2020 Category: Cancer & Oncology Authors: Andrew J. Cowan, MD Source Type: news

Staging Guidelines May be Missing Biomarkers that Affect Outcomes in OPSCC
Researchers suggested that the 2017 classifications do not currently allow for uniform stratification and proper outcome prognostication for surgically treated patients with p16-positive oropharyngeal squamous cell carcinoma. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

WHO Strategy Could Help to Reduce Cervical Cancer Mortality
If successfully implemented, researchers found that over the next century, cervical cancer mortality would be reduced by almost 99% and save more than 62 million women ’s lives. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Clinical Combinations Including PD-1 or PD-L1 Inhibitors Demonstrate More Clinical Activity
In this study, most clinical combinations including PD-1 or PD-L1 inhibitors demonstrated more clinical activity than the monotherapy activity of the checkpoint inhibitor alone. (Source: CancerNetwork)
Source: CancerNetwork - February 17, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

ASCproject Demonstrates Effectiveness of Patient-Partnered Approach in Angiosarcoma
The project indicated that using a patient-partnered approach that leverages social media can potentially prevent the challenges often experienced when studying a rare cancer through traditional research models. (Source: CancerNetwork)
Source: CancerNetwork - February 16, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Nina Shah, MD, on the Safety and Efficacy of CAR T-Cell Therapies for Multiple Myeloma
The associate professor of clinical medicine discussed the main side effects of CAR T-cell therapies when treating multiple myeloma, and how to combat them. (Source: CancerNetwork)
Source: CancerNetwork - February 15, 2020 Category: Cancer & Oncology Authors: Nina Shah, MD Source Type: news

FDA Grants Priority Review to Tazemetostat for Relapsed/Refractory Follicular Lymphoma
The submission was primarily based on updated phase II efficacy and safety data for tazemetostat for patients with relapsed or refractory follicular lymphoma who have received at least 2 prior lines of systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Recommendations for Under-Representation of African Americans in Multiple Myeloma
In a workshop conducted by the FDA and the AACR, working groups came together to address disparities in the representation of African Americans in multiple myeloma clinical trials and to create a set of recommendations in an attempt resolve them. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

State of the Science for Multiple Myeloma: Change in the Right Direction
In a workshop conducted by the FDA and AACR, researchers from various institutions discussed the current state of African American outcomes and treatment in multiple myeloma trials and the clinical implications. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Grants Priority Review to Tucatinib for HER2-Positive Breast Cancer Treatment
The FDA granted a priority review to a new drug application submitted by Seattle Genetics, Inc. for tucatinib to treat patients with HER2-positive breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 14, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

No Association Between Radiofrequency Radiation Exposure and Tumor Development
In a risk analysis, the FDA found that there is not sufficient evidence to support a causal relationship between radiofrequency exposure and tumorigenesis. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Patient-Reported Outcomes Show Newer Drug Combinations Maintain Quality of Life Longer Than Current Standard-of-Care Treatments
Multiple studies showed improved patient outcomes and increased quality of life (QOL) among various treatments that previously demonstrated clinical benefits. These patient-centric findings, along with a promising new combination therapy for patients with advanced hepatocellular carcinoma (HCC) highlight some of the latest research to come out of the 2020 Gastrointestinal Cancers Symposium, held January 23-25, in San Francisco, California. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Synchronous Bilateral Lung Cancer With Discordant Histology
Medical oncologsts discuss the case of a 70-year old woman with synchronous multiple primary lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Mehmet Sitki Copur, MD, FACP, Rudy P. Lackner, MD, Whitney Wedel, MD, Nikki Lintel, MD, Matthew Stritt, MD, Kalpesh Ganatra, MD Source Type: news

Lung Cancer Mortality Suggested to be Significantly Lower with Volume CT
Among participants who were current or former smokers, the NELSON trial found that volume CT screening enabled a significant reduction of harms without jeopardizing favorable outcomes. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC
The FDA   approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

Isolated Extramedullary Relapse in Acute Lymphoblastic Leukemia: What Can We Do Before and After Transplant?
The case of a 43-year-old male with a history of B-cell acute lymphoblastic leukemia. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Santiago Riviello-Goya, MD, Aldo A. Acosta-Medina, MD, Sergio I. Inclan-Alarcon, MD, Sofia Garcia-Miranda, MD, Christianne Bourlon, MD, MHSc Source Type: news